Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bausch + Lomb Corp reports stellar Q2 performance and raises guidance

Bausch + Lomb Corp's Q2 2024 earnings call showcased robust performance, with revenue growth, margin improvement, and raised guidance reflecting a strong outlook.
The company's emphasis on innovation, operational excellence, and long-term growth strategies highlights a commitment to sustained success and shareholder value.
While facing challenges in specific areas and competitive markets, Bausch + Lomb's focus on balancing growth, margins, and investments positions it well for future opportunities.

Bausch + Lomb Corp (BLCO) reports strong Q3 earnings and raises full-year guidance amidst strategic growth focus

Bausch + Lomb Corp (BLCO) delivered a strong Q3 performance with revenue growth, margin expansion, and raised full-year guidance, reflecting a solid financial outlook.
The company's focus on execution, product launches, and strategic investments is driving growth and profitability across segments, showcasing a resilient business strategy.
While challenges like market dynamics and operational complexities persist, opportunities in market expansion, innovation, and strategic partnerships offer avenues for sustained growth.
Overall, Bausch + Lomb Corp (BLCO) is well-positioned for continued success through its commitment to growth, innovation, and operational excellence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VAUGHAN, ON , Nov. 1, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the #LUMIFYEyeDance Challenge on TikTok has received Business Intelligence Group's (BIG) 2022 Public Relations and Marketing Excellence Award for External Campaign of the Year. "The #LUMIFYEyeDance hashtag received approximately 20 million video views on TikTok – that's six million more views than the LUMIFY hashtag had organically amassed on TikTok before the start of the campaign," said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.

Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations and Marketing Excellence Award for External Campaign of the Year from Business Intelligence Group

New Products Will Focus on Dogs' Eyes, Ears and Overall Wellbeing VAUGHAN, ON , Oct. 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the introduction of Project Watson health care products for dogs in the United States. The new line of products is specifically formulated to help support dogs' eyes, ears and overall wellbeing using high quality and naturally inspired ingredients.

Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs

Four Poster Presentations Will Include Research on Company's Latest Solution That Provides More Moisture on Lenses for Patients1 Bausch + Lomb Will Also Sponsor Nine Educational Events VAUGHAN, Ontario , Oct. 18, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that four scientific poster presentations will feature research evaluating Biotrue Hydration Plus Multi-Purpose Solution during the annual meeting of the American Academy of Optometry (AAO), which will take place in San Diego from Oct. 26-29, 2022. Additionally, Bausch + Lomb will sponsor nine educational events that will include discussion of: Biotrue Hydration Plus; the Bi-Elevation™ technique using Bausch + Lomb's Zenlens® scleral lenses; Revive™ custom soft contact lenses; the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2); several of the company's pharmaceutical products; and dry eye disease (DED), one of the most common ocular surface disorders that affects approximately 18 million Americans1,2.

Bausch + Lomb Announces Presentation of Scientific Data and Analyses Evaluating Biotrue® Hydration Plus Multi-Purpose Solution at American Academy of Optometry Annual Meeting

VAUGHAN, ON , Oct. 4, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m.

Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2

VAUGHAN, ON , Oct. 3, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of enhanced Ocuvite Adult 50+ eye vitamin with 30 micrograms of vitamin D, an antioxidant proven to help support healthy cell function, which is key to protecting eye health.* The enhanced Ocuvite vitamin will replace the currently offered Ocuvite Adult 50+.

Bausch + Lomb Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation With Vitamin D

One Podium and Two Poster Presentations Will Highlight Pre-Clinical and Clinical Data for Investigational Treatment NOV03, as well as Data from Company's Unique ARMOR Surveillance Study VAUGHAN, ON , Sept. 27, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept.

Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress

Bausch + Lomb Will Sponsor Two Educational Events on Dry Eye Disease VAUGHAN, ON , Sept. 26, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academy of Ophthalmology (AAO), which will take place in Chicago from Sept.

Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting

VAUGHAN, ON , Sept. 21, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that data from the National Eye Institute's (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which was recently published in JAMA Ophthalmology , will be reviewed and discussed among leading eye care professionals during a live, complimentary webinar, "More InSight: A Closer Look at the New AREDS2 Data and What It Means For Patients" on Tuesday, Oct. 18, 2022, from 8:00-9:00 p.m.

Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings

Bausch Health Companies Inc

GameStop

Twitter

Activist investors purchase a majority of publicly traded shares in companies they believe need to be improved. It doesn't always work out for the company or its shareholders, so let's examine what investors need to know about these stocks.

Recent Investments By Top Activist Investors Include Bausch + Lomb, Twitter, BBBY & GameStop - Buyers Beware

New Report Reveals Vision Loss a Concern for Aging Americans Surveyed, But Majority Are Unaware Age-related Macular Degeneration Is a Leading Cause of Blindness VAUGHAN, Ontario , Sept. 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today released a report of survey results from the company's first annual Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the 'blind spots' that may exist in the understanding and awareness of Age-related Macular Degeneration (AMD), a leading cause of vision loss for those over age 501 and the leading cause of blindness for the 65+ population2.

First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+

PDUFA Action Date is June 28, 2023 VAUGHAN, Ontario and HEIDELBERG, Germany , Sept. 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for investigational treatment NOV03 (perfluorohexyloctane).

Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)

Expansion Offering Enhances and Broadens Bausch + Lomb's Surgical Portfolio with Unique and Clinically Proven Comprehensive Dye Platform VAUGHAN, ON and CASORIA, Italy , Sept. 1, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Alfa Instruments s.r.l.

Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments s.r.l. Intraocular Dyes

VAUGHAN, ON , Aug. 29, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief executive officer; Sam Eldessouky, executive vice president and chief financial officer; and Arthur J.

Bausch + Lomb Announces Participation at Upcoming Investor Conferences

Bausch + Lomb offers a variety of lenses that provide a competitive advantage for every type of consumer. The long-term outlook looks bright due to the strong catalysts, but the short-term outlook is mixed due to the IPO lock-up date.

Bausch + Lomb: Strong Buy After IPO Lock-Up Date

The U.S. IPO market is ice cold following a hot 2021. One May IPO, Bausch + Lomb, is a household name with high uncertainty regarding a planned spinoff and a key drug.

Bausch + Lomb: Traders Eye A Key IPO Lockup Date On This Rangebound Stock

Doximity

BLCO vs. DOCS: Which Stock Is the Better Value Option?

BLCO vs. DOCS: Which Stock Should Value Investors Buy Now?

Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Arthur Shannon - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi Craig Bijou - Bank of America Imron Zafar - Deutsche Bank Doug Miehm - RBC Capital Markets Yatin Suneja - Guggenheim Partners Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Zack Weiner - Jefferies Operator Good morning, and welcome to the Bausch + Lomb's Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode.

Bausch + Lomb Corporation (BLCO) CEO Joseph Papa on Q2 2022 Results - Earnings Call Transcript

Shares of Bausch + Lomb Corp. BLCO, +4.15% were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022. Bausch had earnings of $5 million, or 1 cent per share, in the second quarter of the year, down from $44 million, or 13 cents per share, in the same quarter a year ago.

Bausch + Lomb beats earnings and revenue expectations; stock is up 3%

Second-Quarter 2022 Financial Results Revenues of $941 Million GAAP Net Income of $5 Million Adjusted EBITDA (non-GAAP) 1  of $182 Million GAAP Cash Flow from Operations of $156 Million Reported Revenues Grew 1%, and Organic Revenues1, 2  Grew 6%, Driven by Strong Performance in Vision Care and Surgical Segments Reaffirmed 2022 Full-Year Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Ranges VAUGHAN, ON , Aug. 4, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2022 financial results. "In the second quarter, Bausch + Lomb delivered strong results that demonstrate the advantages of our integrated eye care platform, the durability of our leading brands and the ability of our teams to simultaneously execute on business performance and drive innovation," said Joseph C.

Bausch + Lomb Announces Second-Quarter 2022 Results

Wink, Blink and Dance with Your Eyes for a Chance to Win a Makeover with Vincent Oquendo, Celebrity Makeup Artist and LUMIFY® Redness Reliever Eye Drops Brand Ambassador, and Participate in LUMIFY® National Sampling Tour VAUGHAN, ON , July 28, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the #LUMIFYEyeDance Challenge on TikTok. The #LUMIFYEyeDance will challenge consumers to dance with their eyes to the beat of the LUMIFY® audio track for a chance to win an A-List makeover with celebrity makeup artist and LUMIFY® eye drops brand ambassador, Vincent Oquendo.

Bausch + Lomb Launches the #LUMIFYEyeDance Challenge on TikTok

Bausch + Lomb Has Made an Equity Investment in Sanoculis and Has Entered into an Exclusive European Distribution Agreement for MIMS® Minimally Invasive Surgical Procedure VAUGHAN, ON and TEL AVIV, Israel , July 28, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and Sanoculis, an Israeli ophthalmic medical device start-up company, today announced they have entered into strategic agreements designed to address unmet needs in glaucoma. The companies have entered into an exclusive European distribution agreement for Sanoculis' Minimally Invasive Micro Sclerostomy ("MIMS®"), an innovative minimally invasive surgical procedure for the treatment of glaucoma.

Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma

Study Intended to Support FDA Pre-Market Approval Filing   VAUGHAN, ON , July 26, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas® TENEO™ excimer laser* for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for hyperopia with astigmatism. "The initiation of this study is an important step toward our goal of bringing the Technolas® TENEO™ excimer laser to the United States, where, if approved, it could become the first significant LASIK innovation in more than a decade," said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.

Bausch + Lomb Enrolls First Patient in LASIK Clinical Trial Evaluating Use of Technolas® TENEO™ Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism

Medtronic

Meihua International Medical Technologies Co

Tenon Medical Inc

Virax Biolabs Group Ltd

At least one group is bullish about the outlook for the medtech industry: venture capitalists.

Investors May Want to Follow Progress of VC-Backed Medtechs

VAUGHAN, Canada , July 25, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2022 financial results on Thursday, Aug. 4, 2022. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m.

Bausch + Lomb Will Release Second-Quarter 2022 Financial Results on August 4

VAUGHAN, ON , July 20, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better and subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), announced Joseph C. Papa has stepped down as chair of the Board of Directors of the Company (the "Board").

News for Bausch + Lomb Corp Stock (BLCO)